Mahesh Akram Discloses 30.38M Share Stake in Amneal Pharma
Ticker: AMRX · Form: SC 13G · Filed: Jan 5, 2024 · CIK: 1723128
Complexity: simple
Sentiment: neutral
Topics: insider-holding, beneficial-ownership, pharmaceuticals
TL;DR
**Mahesh Akram just revealed a massive 30.38 million share stake in Amneal Pharma, giving him serious voting power.**
AI Summary
Mahesh Akram, an individual, reported beneficial ownership of 30,384,769 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock as of January 1, 2024. This represents a significant stake, indicating a substantial personal investment in the pharmaceutical company. This matters to investors because a large individual holding can signal confidence in the company's future, but also means a single person has considerable voting power, potentially influencing corporate decisions.
Why It Matters
This filing reveals a major individual shareholder's significant stake, which could influence Amneal Pharmaceuticals' governance and strategic direction.
Risk Assessment
Risk Level: medium — A large individual holding can create concentration risk, as one person's decisions or divestments could significantly impact the stock.
Analyst Insight
Investors should monitor future filings by Mahesh Akram for any changes in his ownership, as a significant increase or decrease could signal his evolving confidence in Amneal Pharmaceuticals.
Key Numbers
- 30,384,769 — Shares Beneficially Owned (Mahesh Akram's sole voting power in Amneal Pharmaceuticals)
- $0.01 — Par Value (Par value per share of Amneal Pharmaceuticals Class A Common Stock)
Key Players & Entities
- Mahesh Akram (person) — reporting person, beneficial owner of shares
- Amneal Pharmaceuticals, Inc. (company) — issuer of the securities
- 30,384,769 (dollar_amount) — number of shares beneficially owned by Mahesh Akram
- January 1, 2024 (date) — date of event requiring the filing
- Class A Common Stock (company) — type of securities owned
Forward-Looking Statements
- Mahesh Akram will maintain a significant stake in Amneal Pharmaceuticals for the foreseeable future. (Mahesh Akram) — medium confidence, target: 2025-01-01
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person in this SC 13G filing is Mahesh Akram, as stated under 'NAMES OF REPORTING PERSONS' on the cover page.
What is the name of the issuer whose securities are being reported?
The issuer is Amneal Pharmaceuticals, Inc., as identified under 'Name of Issuer' and 'COMPANY CONFORMED NAME' in the filing.
How many shares of Amneal Pharmaceuticals, Inc. Class A Common Stock does Mahesh Akram beneficially own with sole voting power?
Mahesh Akram beneficially owns 30,384,769 shares with sole voting power, as indicated in 'NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER' on the cover page.
What is the CUSIP number for the Class A Common Stock of Amneal Pharmaceuticals, Inc.?
The CUSIP number for the Class A Common Stock is 03168L105, as listed under 'CUSIP Number' in the filing.
What was the date of the event that required the filing of this statement?
The date of the event which required the filing of this statement was January 1, 2024, as specified under 'Date of Event Which Requires Filing of this Statement'.
Filing Stats: 1,086 words · 4 min read · ~4 pages · Grade level 10.6 · Accepted 2024-01-05 16:09:52
Key Financial Figures
- $0.01 — ssuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168
Filing Documents
- sc13g.htm (SC 13G) — 49KB
- 0000898432-24-000029.txt ( ) — 50KB
(a)
Item 1(a). Name of Issuer: Amneal Pharmaceuticals, Inc.
(b)
Item 1(b). Address of Issuer's Principal Executive Offices: 400 Crossing Boulevard Bridgewater, NJ 08807
(a)
Item 2(a). Name of Person Filing: Akram Mahesh
(b)
Item 2(b). Address of Principal Business Office or, if none, Residence: c/o Tattva Fiduciary Company 100 West Liberty Street, 10 th Floor Reno, NV 89501
(c)
Item 2(c). Citizenship: United States
(d)
Item 2(d). Title of Class of Securities: Class A Common Stock of the Issuer
(e)
Item 2(e). CUSIP Number: 03168L105 Item 3. Not applicable. Item 4. (a) See Item 9 of the cover pages to this Schedule 13G for the aggregate number of Class A Common Stock that are beneficially owned by the Reporting Person as of January 1, 2024. (b) See Item 11 of the cover pages to this Schedule 13G for the percentage of Class A Common Stock that are beneficially owned by the Reporting Person as of January 1, 2024. (c) See Items 5 through 8 of the cover pages to this Schedule 13G for the number of Class A Common Stock that are beneficially owned by the Reporting Person as of January 1, 2024 as to which there is sole or shared power to vote or direct the vote, and sole or shared power to dispose or direct the disposition. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following . Item 6. Effective on January 1, 2024, the Reporting Person entered into a Stock Purchase and Sale Agreement with Gautam Patel ("Patel"), pursuant to which the Reporting Person purchased from Patel 1,000 shares of the common stock of Tattva Fiduciary Company ("Tattva"), which constitute all of the issued and outstanding common stock of Tattva (the "Purchase Transaction"). Tattva is the sole trustee of certain trusts (each, a "Trust" and collectively, the "Trusts") that hold Class A Common Stock of the Issuer. In connection with the Purchase Transaction, the Reporting Person also became the sole owner of Tattva, effective as of January 1, 2024. As a result of the Purchase Transaction, the Reporting Person has sole voting and dispositive power over, and may deemed to have beneficial ownership of, the shares of Class A Common Stock of the Issuer held by the Trusts of which Tattva is the s